Adaptimmune

📍 Abingdon, United Kingdom🗓 Founded 2008👥 428 employees💰 Last funded Sep 2015
Biotechnology Research🌐 adaptimmune.com
Website LinkedIn
Adaptimmune, a leader in T-cell therapy, is a multinational, clinical-stage biopharmaceutical company focused on developing novel immunotherapies using its proprietary SPEAR T-cell receptor platform to treat solid tumors, which has the potential to transform the treatment of cancer. Our proprietary SPEAR T-cell platform has generated a strong pipeline of affinity-enhanced T-cell therapies, with multiple INDs open. We use these therapies to harness the body's own immune system to find and destroy diseased cells. Our SPEAR TCR therapies offer promise to patients that often have no other options. We are working hard to make that promise a reality. We are based in the UK, in Oxford, and in the US, in Philadelphia. For more information about Adaptimmune, please visit www.adaptimmune.com. If interested in joining our fast growing team, click on the careers tab of this page.
2
Total investors
0
Early stage
0
Mid stage
2
Late stage
2008
Founded

Investors

2 investors
All
Early stage
Mid stage
Late stage
Investor geography2 countries
United Kingdom
1
United States
1
Frequently asked questions
Who invested in Adaptimmune?
Adaptimmune has 2 investors on record on gritt.io and 2 late-stage investors.
When did Adaptimmune last raise funding?
The most recent investment in Adaptimmune recorded on gritt.io was in September 2015.
When was Adaptimmune founded?
Adaptimmune was founded in 2008.
What industry is Adaptimmune in?
Adaptimmune operates in Biotechnology Research. Find similar Biotechnology Research investors on gritt.io.
Where is Adaptimmune based?
Adaptimmune is headquartered in Abingdon, United Kingdom.